Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

NCT01443364 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: Certolizumab pegol

Sponsor

UCB Italy s.p.a.